Lysophosphatidic acid receptor 1-6 (LPA1-6)

The Lysophosphatidic acid receptor 1-6 (LPA1-6) family consists of six G protein-coupled receptors (GPCRs) that mediate the diverse biological effects of lysophosphatidic acid (LPA), a potent bioactive lipid [1, 3]. These receptors are divided into two subfamilies: the endothelial differentiation gene (EDG) family (LPA1, LPA2, and LPA3) and the non-EDG family (LPA4, LPA5, and LPA6) [2, 5]. LPA1-6 signaling regulates critical cellular processes such as proliferation, migration, survival, and cytoskeletal reorganization across various tissues, including the nervous, cardiovascular, and immune systems [3, 4]. Dysregulation of the LPA-LPAR axis is heavily implicated in the pathogenesis of several diseases, most notably idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and various cancers where it promotes tumor growth and metastasis [4, 10, 12]. Consequently, these receptors have become significant therapeutic targets, with several LPA1 antagonists currently in clinical development for fibrotic conditions [9, 16]. While LPA1 is the most extensively studied, emerging research into other subtypes like LPA6 highlights their roles in conditions such as congenital hair loss and immune modulation [1, 15, 17].

Other names

LPAR1-6Lysophosphatidic acid receptorsEDG receptors (LPA1-3)Non-EDG LPA receptors (LPA4-6)P2Y5 (LPA6)GPR23 (LPA4)GPR92 (LPA5)

Drugs targeting this family primarily act as antagonists to block the binding of lysophosphatidic acid (LPA) to its receptors, thereby inhibiting downstream signaling pathways (such as Rho/ROCK, PI3K/Akt, and MAPK) that drive fibrosis and tumor progression. Some subtypes, like LPA2, are also targeted by agonists for potential cytoprotective effects.